Pharma News | Biotech News | Global Pharma

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Request a free trial

Scrip

Spotlight On Israel Market Challenges Stunting Biopharma Growth

By Lucie Ellis 24 Apr 2018

Scrip investigates the big issues Israel's biopharma sector need to overcome in order to maintain momentum and achieve sustainable success.

Scrip

Merck KGaA Down-Plays Further Deals After Consumer Health Sell-Off

By John Davis 20 Apr 2018

The sale of the Merck KGaA consumer health business to Procter & Gamble could eventually give the German multinational greater flexibility in business development activities, but reducing net debt has first claim on the funds.

Scrip

TVM Raises White Flag On Biovertis and Morphochem

By Mike Ward 20 Apr 2018

Denoive acquires from TVM Capital both Biovertis and Morphochem, plus a Phase II ready antibiotic asset, for an initial 4% stake worth €900,000. Since their formation, Biovertis and Morphochem have had more than $96m invested in them.

Scrip

IPO Update: Will Declining Returns Slow Fast Pace Of Biopharma Offerings?

By Mandy Jackson 06 Apr 2018

Offerings by Homology, Unum and Genprex at the end of March brought the first quarter's biopharma IPO total to 14 in the US, putting 2018 on track to beat the 2017 total of 42. But with the average return for this year's IPOs dropping, the pace of offerings could slow.

Scrip

FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay

By Jessica Merrill 06 Apr 2018

CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.

Scrip

GSK Gains Clarity For Pharma Focus Through Novartis Consumer JV Buy

By Mandy Jackson 29 Mar 2018

GSK removed some uncertainty about how much it could invest in pharma R&D and business development by purchasing Novartis' share of the firms' Consumer Healthcare Joint Venture. Now it can more accurately allocate capital as it prepares for battle in HIV and braces for Advair generics.

Scrip

J&J Stays Within Price Pledge, But Average Doesn't Tell The Whole Story, Analyst Says

By Brenda Sandburg 29 Mar 2018

Bernstein analyst looks into J&J's average net price decline in 2017 and notes average sales price hikes for growth products Darzalex and Imbruvica are offset by price cuts for drugs facing competition. All products had single digit increases, though.

Scrip

Getting Women On Boards: LifeSci Advisors' After-Party Mission Is Valued But Achieving Results Is Hard

By Eleanor Malone 20 Mar 2018

LifeSci Advisors has thrown its back into getting more women on boards, and its efforts have been praised. However, with just 13 women placed in a year and a half, the task is not an easy one.

Scrip

From Pharma Insider To Payer: Witty To Lead United's Optum

By Jessica Merrill 20 Mar 2018

Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.

Scrip

Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

By Ian Schofield 05 Mar 2018

Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

Scrip

Workforce Roundtable Part 1: Recruiting Biopharma Leaders As The Talent Pool Shrinks

By Mandy Jackson 28 Feb 2018

As Baby Boomers age out of the workforce, they'll be replaced in biopharma C-suites and boardrooms by a younger, more female and racially diverse group. A panel of current and former life science CEOs, venture investors and recruiters discuss the challenges and opportunities ahead.

Scrip

Preparing Emerging Biotechs For The Best Deals

By Lucie Ellis 23 Feb 2018

As the market for pharma and biotech deal making heats up in 2018, Scrip looks at the process of valuing novel companies with emerging data and collects best advice from experts on how start-ups should pitch to potential pharma partners.

Scrip

How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch

By Bowman Cox 23 Feb 2018

An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.

Scrip

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

By Mandy Jackson 22 Feb 2018

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Scrip

Exploring Sanofi's Revamped IO Pipeline

By Lucie Ellis 21 Feb 2018

In an exclusive interview, Sanofi's head of oncology development Joanne Lager explains how the French big pharma could make a comeback in cancer this year and highlights its immunotherapy combination opportunities.